Equities research analysts predict that Johnson & Johnson (NYSE:JNJ) will report earnings of $1.88 per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Johnson & Johnson’s earnings. The lowest EPS estimate is $1.85 and the highest is $2.00. Johnson & Johnson reported earnings of $1.97 per share in the same quarter last year, which would indicate a negative year over year growth rate of 4.6%. The firm is expected to issue its next quarterly earnings results on Tuesday, January 28th.
On average, analysts expect that Johnson & Johnson will report full-year earnings of $8.65 per share for the current year, with EPS estimates ranging from $8.58 to $8.69. For the next year, analysts anticipate that the business will post earnings of $9.12 per share, with EPS estimates ranging from $9.02 to $9.25. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $2.00 by $0.12. The firm had revenue of $20.73 billion for the quarter, compared to analyst estimates of $20.14 billion. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. Johnson & Johnson’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the previous year, the firm earned $2.05 earnings per share.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $25,000. Krane Funds Advisors LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $26,000. Financial Advantage Inc. bought a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $28,000. Crewe Advisors LLC boosted its stake in Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares during the period. Finally, Permanens Capital L.P. boosted its stake in Johnson & Johnson by 50.0% during the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock valued at $42,000 after purchasing an additional 100 shares during the period. Institutional investors own 72.22% of the company’s stock.
Shares of JNJ stock opened at $131.27 on Thursday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The stock’s 50-day moving average is $130.88 and its two-hundred day moving average is $133.92. The firm has a market cap of $350.04 billion, a P/E ratio of 16.05, a PEG ratio of 2.25 and a beta of 0.69.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $0.95 per share. The ex-dividend date is Monday, November 25th. This represents a $3.80 annualized dividend and a dividend yield of 2.89%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: What is an Initial Public Offering (IPO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.